Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia
A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Pfizer Investigational Site
-
Bochum, Germany
- Pfizer Investigational Site
-
Duesseldorf, Germany
- Pfizer Investigational Site
-
Frankfurt, Germany
- Pfizer Investigational Site
-
Goeppingen, Germany
- Pfizer Investigational Site
-
Hamburg, Germany
- Pfizer Investigational Site
-
Hattingen, Germany
- Pfizer Investigational Site
-
Jena, Germany
- Pfizer Investigational Site
-
Nuernberg, Germany
- Pfizer Investigational Site
-
Wiesbaden, Germany
- Pfizer Investigational Site
-
-
-
-
-
L'Aquila, Italy
- Pfizer Investigational Site
-
Perugia, Italy
- Pfizer Investigational Site
-
Pisa, Italy
- Pfizer Investigational Site
-
Roma, Italy
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Spain
- Pfizer Investigational Site
-
Granada, Spain
- Pfizer Investigational Site
-
Salamanca, Spain
- Pfizer Investigational Site
-
Sevilla, Spain
- Pfizer Investigational Site
-
Valencia, Spain
- Pfizer Investigational Site
-
-
Madrid
-
Leganes, Madrid, Spain
- Pfizer Investigational Site
-
-
-
-
-
Glasgow, United Kingdom
- Pfizer Investigational Site
-
Oldham, Lancashire, United Kingdom
- Pfizer Investigational Site
-
Portsmouth, United Kingdom
- Pfizer Investigational Site
-
-
Cleveland
-
Middlesbrough, Cleveland, United Kingdom
- Pfizer Investigational Site
-
-
Surrey
-
Addlestone, Surrey, United Kingdom
- Pfizer Investigational Site
-
-
Sussex
-
Chicester, Sussex, United Kingdom
- Pfizer Investigational Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States
- Pfizer Investigational Site
-
-
Arkansas
-
Little Rock, Arkansas, United States
- Pfizer Investigational Site
-
-
California
-
Duarte, California, United States
- Pfizer Investigational Site
-
-
Colorado
-
Denver, Colorado, United States
- Pfizer Investigational Site
-
-
Florida
-
Palm Beach Gardens, Florida, United States
- Pfizer Investigational Site
-
-
Illinois
-
Oak Brook, Illinois, United States
- Pfizer Investigational Site
-
-
Mississippi
-
Flowood, Mississippi, United States
- Pfizer Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, United States
- Pfizer Investigational Site
-
-
Ohio
-
Toledo, Ohio, United States
- Pfizer Investigational Site
-
-
Oregon
-
Portland, Oregon, United States
- Pfizer Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, United States
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, United States
- Pfizer Investigational Site
-
-
Wisconsin
-
Madison, Wisconsin, United States
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of PHN with pain present for at least three months after the healing of a Herpes Zoster skin lesion.
- Subjects must have completed the Daily Pain Rating Scale in the electronic diary at least 4 times during screening and have an average daily pain rating score of greater than or equl to 4 during the 7 +/- 3 days prior to randomization (Visit 2).
Exclusion Criteria:
- History of neurolytic or neurosurgical therapy for PHN.
- Presence of any severe pain associated with conditions other than PHN that may confound the assessment or self-evaluation of the pain due to PHN.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Onset meaningful pain reduction
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Markman JD, Jensen TS, Semel D, Li C, Parsons B, Behar R, Sadosky AB. Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials. Pain Pract. 2017 Jul;17(6):718-728. doi: 10.1111/papr.12516. Epub 2016 Dec 1.
- Schug SA, Parsons B, Almas M, Whalen E. Effect of Concomitant Pain Medications on Response to Pregabalin in Patients with Postherpetic Neuralgia or Spinal Cord Injury-Related Neuropathic Pain. Pain Physician. 2017 Jan-Feb;20(1):E53-E63.
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Neuralgia
- Neuralgia, Postherpetic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anti-Anxiety Agents
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Pregabalin
Other Study ID Numbers
Other Study ID Numbers
- A0081004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.